Releases Geral
Curia Recognized on India Pharma Outlooks 2023 List of Top 10 CDMO Companies in India
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 5 de dezembro de 2023
Curia Global, Inc.
ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine.
This recognition acknowledges the contributions of Curias Aurangabad and Hyderabad sites. The Aurangabad facility provides contract manufacturing of active pharmaceutical ingredients (APIs) and intermediates, and the Hyderabad site includes the Hyderabad Research Center with expertise in medicinal chemistry and chemical and analytical development. These sites also house Curias quality control center and Global Shared Services (GSS) center, which support the companys global organization, enabling process standardization and scalability.
Curias focus on continuous improvement for its comprehensive suite of services and investments in innovative technologies position the company as a strong partner to pharmaceutical and biotechnology companies across the drug research, development and manufacturing continuum. The report also highlights Curias commitment to being an employer of choice, providing employees with a workplace culture rich in opportunities for professional development and recognition.
This achievement is a testament to the talent and hard work from our Aurangabad and Hyderabad facilities, and it is a well-deserved honor for the team, said Philip Macnabb, CEO, Curia. Our India sites relentlessly pursue excellence and are vital to our goal of improving patients lives.
India Pharma Outlooks editorial board compiled the list with a panel of judges with expertise in the industry, including CXOs and analysts. Winners were chosen for their impact on Indias economy through job creation, fostering research and development and for their high-quality offerings in the pharmaceutical and biotechnology industry.
About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curias nearly 4,000 employees at 27 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/faac19ea-f26f-4811-946f-e03d10480984
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Combater a gordofobia é objetivo de manual para comunicação
6 de março de 2024São Paulo--(DINO - 06 mar, 2024) - Com o objetivo de conscientizar, combater a gordofobia e desmistificar preconceitos relacio
Saiba Mais -
Releases Geral LambdaTest Announces Integration with Bitrise to Streamline Mobile App Testing
16 de fevereiro de 2024Lambdatest, Inc. San Francisco, Feb. 16, 2024 (GLOBE NEWSWIRE) — LambdaTest, a leading cloud-based unified testing platform announces its integration with Bitrise, the mobile CI/CD platform as
Saiba Mais -
Releases Geral Internet das Coisas escala o seu potencial com as redes 5G
3 de agosto de 2023DINO DIVULGADOR DE NOTÍCIAS Rio de Janeiro–(DINO – 03 ago, 2023) – Duas inovações tecnológicas estão em expansão e visam, em conjunto,
Saiba Mais